Stockreport

TYME and The Joseph Ahmed Foundation Announce First Patient Dosed in Phase II (HopES) Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with High-Risk Sarcomas

Tyme Technologies, Inc.  (TYME) 
Last tyme technologies, inc. earnings: 2/5 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: tymeinc.com/investors
PDF New oral approach aimed at disrupting cancer metabolism in high-risk sarcomas; 12,000 cases annually in U.S. aloneOral SM-88 represents a new approach designed to select [Read more]